Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 1.8% - Here's What Happened

Key Points

• Silverback Therapeutics stock decreased by 1.8%, closing at $9.72 after trading as low as $9.64 during the day.
• The company has a market cap of $350.48 million, a PE ratio of -4.02, and a notable increase in trading volume of 246% compared to average levels.
• Silverback Therapeutics focuses on developing tissue-targeted therapeutics for conditions like chronic viral infections and cancer, with a specific product aimed at treating chronic hepatitis B.

Silverback Therapeutics, Inc. (NASDAQ:SBTX - )'s stock price was down 1.8% during mid-day trading on Thursday . The stock traded as low as $9.64 and last traded at $9.72. Approximately 1,170,311 shares changed hands during trading, an increase of 246% from the average daily volume of 337,931 shares. The stock had previously closed at $9.90.

Silverback Therapeutics Stock Down 1.8%

The stock has a market cap of $350.48 million, a PE ratio of -4.02 and a beta of 0.60. The firm has a 50-day simple moving average of $11.12 and a 200-day simple moving average of $13.98.

Silverback Therapeutics Company Profile

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.